Vonoprazan's As-Needed NERD Bet: First-Mover Opportunity Meets Unproven Regulatory Template

Phathom Initiates Registrational Phase 3 for As-Needed VOQUEZNA in NERD

Phathom Pharmaceuticals has initiated patient screening for pHalcon-NERD-302, a registrational Phase 3 study evaluating as-needed VOQUEZNA (vonoprazan) 10 mg for adults with Non-Erosive Gastroesophageal Reflux Disease (NERD). This multicenter, randomized, double-blind, placebo-controlled study builds on positive Phase 2 results and aims to enroll approximately 500 patients across 80 U.S. sites. The primary endpoint, assessed at Week 12, focuses on complete and sustained heartburn relief within 24 hours post-dosing. Topline results are anticipated in the first quarter of 2028, with successful outcomes intended to support a label expansion for VOQUEZNA for as-needed NERD treatment, addressing a significant unmet need as current PPIs are not approved for this regimen.

• The pHalcon-NERD-302 study is a multicenter, randomized, double-blind, placebo-controlled Phase 3 trial investigating VOQUEZNA 10 mg as an as-needed treatment for Non-Erosive GERD. It aims to enroll approximately 500 adults experiencing heartburn at least four days per week across 80 U.S. sites. The study's primary objective is to assess whether as-needed VOQUEZNA can provide rapid and sustained heartburn relief, potentially broadening its utility for patients with intermittent symptoms.
• Non-Erosive GERD is characterized by unpredictable heartburn, and current proton pump inhibitors (PPIs) typically require continuous daily use, lacking an approved as-needed option in the U.S. for this condition. This study addresses a significant patient and physician desire for an on-demand treatment that can provide rapid acid suppression and sustained heartburn control over 24 hours, building on promising Phase 2 data that supports this approach.
• Successful completion of the pHalcon-NERD-302 study is intended to support a potential regulatory submission for a label expansion of VOQUEZNA to include as-needed treatment of heartburn episodes in NERD patients. This would represent a novel treatment regimen, as PPIs are not currently approved for as-needed use in NERD in the U.S., offering a new therapeutic option and significant market opportunity for Phathom Pharmaceuticals.

The Unmet Need for As-Needed Treatment in NERD

NERD represents the most prevalent GERD phenotype, yet current pharmacological strategies leave a substantial proportion of patients with inadequate symptom control. The heterogeneity of the NERD population — encompassing true acid reflux, weakly acidic reflux, and functional heartburn — complicates both diagnosis and treatment selection.

• Suboptimal PPI response in poorly defined NERD cohorts. The pooled estimate of complete heartburn relief after 4 weeks of PPI therapy is 0.49 (95% CI: 0.44–0.55) in endoscopy-negative patients, rising to 0.73 (95% CI: 0.69–0.77) only when NERD is defined by both negative endoscopy and a positive pH test. This disparity indicates that low response rates in many studies reflect inclusion of patients without true reflux disease rather than a genuine PPI failure in confirmed NERD.

• Diagnostic heterogeneity and misclassification. Distinguishing NERD from functional heartburn and hypersensitive esophagus remains a clinical challenge. Rome IV criteria restrict GERD diagnosis to abnormal acid exposure time alone, yet multiple studies support the diagnostic utility of weakly acidic reflux assessment, the post-reflux swallow-induced peristaltic wave (PSPW) index, and mean nocturnal baseline impedance (MNBI) — parameters that can identify hypersensitive esophagus even when acid exposure time is normal and symptom association probability (SAP) and symptom index (SI) are negative.

• Unreliability of symptom association metrics. SAP cannot accurately distinguish reflux hypersensitivity from functional esophageal symptoms in PPI-refractory GERD. The difference in symptom association parameters that leads to an SAP-positive diagnosis is small (0.48% in the pH-negative/oesophagitis-negative group), and significant day-to-day variability in SAP values further limits its clinical utility. Pre-surgery SAP was not associated with response to anti-reflux surgery in one cohort of 58 patients.

• Persistent unmet needs with standard PPI therapy. Even optimally dosed PPIs provide inadequate control of nocturnal heartburn and extraesophageal symptoms in a meaningful subset of NERD patients. Weakly acidic reflux, visceral hypersensitivity, delayed gastric emptying, and psychological comorbidity are recognized drivers of PPI-refractory symptoms that are not addressed by acid suppression alone.

• Emerging but limited alternatives. P-CABs such as vonoprazan and tegoprazan offer rapid onset and sustained acid suppression and have demonstrated symptom control in non-erosive reflux disease compared with placebo; however, the meta-analytic evidence base for PCABs in NERD specifically remains limited, with the predominance of available trial data focused on erosive esophagitis. Adjunctive strategies such as sodium alginate added to omeprazole have shown benefit — complete heartburn resolution was significantly more common with omeprazole plus sodium alginate (56.7%) than with omeprazole alone (25.7%) in one randomized trial of Japanese NERD patients — but long-term data and broader validation are lacking.

VOQUEZNA's Differentiated Approach for Episodic NERD Heartburn

Vonoprazan has demonstrated clinically meaningful superiority over placebo across multiple endpoints in patients with non-erosive reflux disease (NERD). In a phase 3 randomized trial evaluating on-demand dosing, vonoprazan 10 mg, 20 mg, and 40 mg achieved complete and sustained heartburn relief within 3 hours and sustained for 24 hours in 56.0%, 60.6%, and 70.0% of evaluable episodes, respectively, compared with 27.3% for placebo (p < 0.0001 versus placebo for each vonoprazan group). Relief was evident as early as 1 hour post-dose, and no serious treatment-emergent adverse events were reported, supporting vonoprazan as a potential alternative to continuous daily acid suppression for episodic heartburn in NERD.

Vonoprazan also demonstrated significant benefit on nocturnal NERD symptoms in a pre-specified analysis of a phase 3 randomized trial. Among 772 subjects, the mean percentage of heartburn-free nights at week 4 was 59.9% for vonoprazan 10 mg and 56.4% for vonoprazan 20 mg, versus 43.3% for placebo (least square mean differences of 16.5% and 13.1%, respectively; p < 0.0001 for both). Both doses significantly improved N-GSSIQ total score, nocturnal symptom severity subscale, and concern about nocturnal GERD subscale versus placebo (p < 0.005 or better for all comparisons), with benefits sustained through an additional 20 weeks of follow-up.

In the broader context of acid suppression for NERD, a systematic review and meta-analysis of tegoprazan — another potassium-competitive acid blocker (PCAB) — reported symptom resolution rates of 42.5% to 48.9% in NERD patients versus 24.2% with placebo, with adverse events described as mild and comparable to proton pump inhibitors (PPIs). Separately, evidence from a 2008 study of esomeprazole in symptomatic reflux patients indicated that PPI response in NERD is heterogeneous and dependent on symptom-reflux association: patients without evidence of pathologic reflux on 24-hour pH recording responded less favorably to PPI treatment than those with a positive symptom-reflux association or pathologic acid exposure, underscoring a recognized limitation of standard-of-care PPI therapy in this population.

VOQUEZNA's Strategic Bid for On-Demand NERD Relief

For millions experiencing the unpredictable discomfort of Non-Erosive Gastroesophageal Reflux Disease (NERD), effective and rapid relief remains an elusive goal. Current treatment paradigms, largely centered around daily proton pump inhibitors (PPIs), often fall short for episodic symptoms, as PPIs are not approved for on-demand use and exhibit a slower onset of action. This creates a significant unmet medical need for a therapy that can provide quick, sustained relief when symptoms strike.

Enter vonoprazan, a potassium-competitive acid blocker (P-CAB) with a distinct pharmacological profile. Research indicates P-CABs offer a more potent, rapid, and longer-lasting antisecretory effect compared to PPIs, largely due to their unique mechanism of action that is unaffected by the gastric secretory state. This rapid onset and sustained action are precisely what patients with episodic NERD require. Phathom Pharmaceuticals' initiation of a registrational Phase 3 study for as-needed VOQUEZNA (vonoprazan) 10 mg is a strategic move to capitalize on this advantage, building on promising Phase 2 data that demonstrated significant complete and sustained heartburn relief within hours of on-demand dosing.

A successful outcome in this Phase 3 trial could fundamentally reshape the NERD treatment landscape. It would not only secure a crucial label expansion for VOQUEZNA, but also establish a new standard of care, offering a differentiated option where PPIs currently lack an approved on-demand indication. This could solidify the P-CAB class as a superior alternative for specific acid-related disorders, granting Phathom a first-mover advantage in this segment. However, the path is not without its challenges. The trial must demonstrate consistent efficacy, especially given that a previous Phase 3 study for daily vonoprazan in NERD showed mixed results. Furthermore, while P-CABs offer clear mechanistic advantages, the real-world uptake will depend on demonstrating a compelling benefit over existing, albeit off-label, patient management strategies. Confirming the long-term safety profile for intermittent dosing in a larger population will also be critical. If successful, VOQUEZNA could empower patients with a truly on-demand solution, marking a pivotal shift in how episodic heartburn is managed.